Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases

Bisphosphonates are a standard treatment for metastatic bone disease, although agents vary in their potential for renal toxicity. This case report describes the reversal of zoledronic acid-induced renal toxicity by switching treatment to ibandronate in a patient with hormone-refractory prostate cancer and bone metastases. Copyright (c) 2008 S. Karger AG, Basel.